We are the Hyperhidrosis Priority Setting Partnership: a collaboration between De Montfort University, the James Lind Alliance and the UK Dermatology Clinical Trials Network.
Hyperhidrosis is a skin condition where an individual has abnormal levels of sweating. It is very common, affecting 1 – 3 % of the population. It affects both sexes and all races equally. It can cause both physical problems and psychological distress, and significantly affect quality of life.
Despite it being widespread, excessive sweating is relatively under-researched compared with other skin conditions that affect a similar number of people.
It is essential that future research into the treatment of hyperhidrosis should focus on the questions that are important to people who have this condition, the people who care for them and the health professionals that treat them. Over 250 patients and clinicians told us about the research questions they wanted to have answered. Following on from this we created a Top Ten list of the most important research questions:
1 Are there any safe and effective permanent solutions for hyperhidrosis?
2 What is the most effective and safe oral treatment (drugs taken by mouth) for hyperhidrosis?
3 What are the most effective and safe ways to reduce sweating in particular areas of the body (e.g. hands, feet, underarms, face, head etc.)?
4 How does hyperhidrosis affect quality of life?
5 Are combinations of different treatments more effective than one type of treatment for hyperhidrosis?
6 What is the most safe and effective treatment for mild to moderate hyperhidrosis?
7 Could targeted therapies or biologics (e.g. antibodies, hormones, stem cells), be effective in treating hyperhidrosis?
8 What is the most effective severity scale that can be used to determine if a person is eligible for hyperhidrosis treatment?
9 What is the safest and most effective surgery for hyperhidrosis?
10 How safe are hyperhidrosis treatments at different stages of life, e.g. childhood, pregnancy and breastfeeding?
For more information please see here: